| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Casticin (0.2-1.0 μM) had no discernible inhibitory impact on 3T3 Swiss Albino and TIG-103 cells, but it dose-dependently reduced the proliferation of KB cells, with an IC50 of 0.23 μM on day 3. Spindle morphology is altered by ricin (0.6 μM), which can result in spindle disorder or partial mitotic spindle disruption [1]. LX2 cell proliferation is dose-dependently inhibited by caucin (0–40 μM). Apoptosis is induced and L02 cell growth is inhibited by caucin (40 μM). Casticin assesses the mRNA levels of TGF-β, collagen α1(I), MMP-2, MMP-9, TIMP-1, and TIMP-2 and inhibits the fibrotic action of TGF-β1 on ECM deposition in LX2 cells [2]. The vitality of 786-O, YD-8, and HN-9 cells is decreased by cacticin (0-8 μM), whereas normal HEL 299 cells are not significantly affected. Casticin (5 μM) decreases stroma levels, vascular endothelial growth factor (VEGF), B-cell lymphoma-extra large (Bcl-xl), Bcl-2, IAP-1/-2, MMP-9, and COX-2 proteins in O, YD-8, and HN-9 cells, and promotes caspase-3 and PPAR cleavage. Additionally, calcin (5 μM) can cause apoptosis, prevent IL-6-induced STAT3 activation, block continuously active STAT3 in tumor cells, and regulate STAT3 activation by altering the activity of upstream STAT3 regulators. Furthermore, Casticin (2.5 μM) improves the therapeutic effect of radiation therapy and the effect of ionizing radiation in 786-O cells [3].
|
|---|---|
| ln Vivo |
Mice with liver impairment induced by BDL and CCl4 exhibit toxic effects on their livers when exposed to 20 mg/kg of cacticin po. In vivo, CCl4 or BDL-induced liver fibrosis is attenuated by cacticin. Casticin blocks TGF-β/Smad signaling in vivo to prevent HSC activation and collagen matrix expression [2].
|
| References |
|
| Additional Infomation |
Casticin is a tetramethoxyflavone that consists of quercetagetin in which the hydroxy groups at positions 3, 6, 7 and 4' have been replaced by methoxy groups. It has been isolated from Eremophila mitchellii. It has a role as an apoptosis inducer and a plant metabolite. It is a tetramethoxyflavone and a dihydroxyflavone. It is functionally related to a quercetagetin.
Casticin has been reported in Artemisia incanescens, Vitex quinata, and other organisms with data available. See also: Chaste tree fruit (part of). |
| Molecular Formula |
C19H18O8
|
|---|---|
| Molecular Weight |
374.3414
|
| Exact Mass |
374.1
|
| CAS # |
479-91-4
|
| PubChem CID |
5315263
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
617.7±55.0 °C at 760 mmHg
|
| Melting Point |
186 - 187 °C
|
| Flash Point |
223.5±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.640
|
| LogP |
2.13
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
576
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PJQLSMYMOKWUJG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18O8/c1-23-11-6-5-9(7-10(11)20)17-19(26-4)16(22)14-12(27-17)8-13(24-2)18(25-3)15(14)21/h5-8,20-21H,1-4H3
|
| Chemical Name |
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,6,7-trimethoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~267.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (16.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6714 mL | 13.3568 mL | 26.7137 mL | |
| 5 mM | 0.5343 mL | 2.6714 mL | 5.3427 mL | |
| 10 mM | 0.2671 mL | 1.3357 mL | 2.6714 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
